PURPOSE: ABT-431 is a chemically stable, poorly soluble prodrug that rapidly converts in vivo to A-86929, a selective dopamine D-1 receptor agonist. This study was designed to evaluate the ability of the AERx pulmonary delivery system to deliver ABT-431 to the systemic circulation via the lung. METHODS: A 60% ethanol formulation of 50 mg/mL ABT-431 was used to prepare unit dosage forms containing 40 microL of formulation. The AERx system was used to generate a fine aerosol bolus from each unit dose that was collected either onto a filter assembly to chemically assay for the emitted dose or in an Andersen cascade impactor for particle size analysis. Plasma samples were obtained for pharmacokinetic analysis after pulmonary delivery and IV dosing of ABT-431 to nine healthy male volunteers. Doses from the AERx system were delivered as a bolus inhalation(s) (1, 2, 4, and 8 mg) and intravenous infusions were given over 1 hr (5 mg). Pharmacokinetic parameters of A-86929 were estimated using noncompartmental analysis. RESULTS: The emitted dose was 1.02 mg (%RSD = 11.0, n = 48). The mass median aerodynamic diameter of the aerosol was 2.9 +/- 0.1 microm with a geometric standard deviation of 1.3 +/- 0.1 (n = 15). Tmax (mean +/- SD) after inhalation ranged from 0.9 +/- 0.6 to 11.5 +/- 2.5. The mean absolute pulmonary bioavailibility (as A-86929) based on emitted dose ranged from 81.9% to 107.4%. CONCLUSIONS: This study demonstrated that the AERx pulmonary delivery system is capable of reproducibly generating fine nearly monodisperse aerosols of a small organic molecule. Aerosol inhalation utilizing the AERx pulmonary delivery system may be an efficient means for systemic delivery of small organic molecules such as ABT-431.
RCT Entities:
PURPOSE:ABT-431 is a chemically stable, poorly soluble prodrug that rapidly converts in vivo to A-86929, a selective dopamine D-1 receptor agonist. This study was designed to evaluate the ability of the AERx pulmonary delivery system to deliver ABT-431 to the systemic circulation via the lung. METHODS: A 60% ethanol formulation of 50 mg/mL ABT-431 was used to prepare unit dosage forms containing 40 microL of formulation. The AERx system was used to generate a fine aerosol bolus from each unit dose that was collected either onto a filter assembly to chemically assay for the emitted dose or in an Andersen cascade impactor for particle size analysis. Plasma samples were obtained for pharmacokinetic analysis after pulmonary delivery and IV dosing of ABT-431 to nine healthy male volunteers. Doses from the AERx system were delivered as a bolus inhalation(s) (1, 2, 4, and 8 mg) and intravenous infusions were given over 1 hr (5 mg). Pharmacokinetic parameters of A-86929 were estimated using noncompartmental analysis. RESULTS: The emitted dose was 1.02 mg (%RSD = 11.0, n = 48). The mass median aerodynamic diameter of the aerosol was 2.9 +/- 0.1 microm with a geometric standard deviation of 1.3 +/- 0.1 (n = 15). Tmax (mean +/- SD) after inhalation ranged from 0.9 +/- 0.6 to 11.5 +/- 2.5. The mean absolute pulmonary bioavailibility (as A-86929) based on emitted dose ranged from 81.9% to 107.4%. CONCLUSIONS: This study demonstrated that the AERx pulmonary delivery system is capable of reproducibly generating fine nearly monodisperse aerosols of a small organic molecule. Aerosol inhalation utilizing the AERx pulmonary delivery system may be an efficient means for systemic delivery of small organic molecules such as ABT-431.
Authors: O Rascol; O Blin; C Thalamas; S Descombes; C Soubrouillard; P Azulay; N Fabre; F Viallet; K Lafnitzegger; S Wright; J H Carter; J G Nutt Journal: Ann Neurol Date: 1999-06 Impact factor: 10.422
Authors: S J Farr; S J Warren; P Lloyd; J K Okikawa; J A Schuster; A M Rowe; R M Rubsamen; G Taylor Journal: Int J Pharm Date: 2000-03-30 Impact factor: 5.875
Authors: M E Ward; A Woodhouse; L E Mather; S J Farr; J K Okikawa; P Lloyd; J A Schuster; R M Rubsamen Journal: Clin Pharmacol Ther Date: 1997-12 Impact factor: 6.875
Authors: M Dershwitz; J L Walsh; R J Morishige; P M Connors; R M Rubsamen; S L Shafer; C E Rosow Journal: Anesthesiology Date: 2000-09 Impact factor: 7.892
Authors: O Rascol; J G Nutt; O Blin; C G Goetz; J M Trugman; C Soubrouillard; J H Carter; L J Currie; N Fabre; C Thalamas; W W Giardina; S Wright Journal: Arch Neurol Date: 2001-02
Authors: K Shiosaki; P Jenner; K E Asin; D R Britton; C W Lin; M Michaelides; L Smith; B Bianchi; S Didomenico; L Hodges; Y Hong; L Mahan; J Mikusa; T Miller; A Nikkel; M Stashko; D Witte; M Williams Journal: J Pharmacol Exp Ther Date: 1996-01 Impact factor: 4.030